You just read:

Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

News provided by

Ampio Pharmaceuticals, Inc.

Mar 24, 2020, 06:30 ET